SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xencor (XNCR) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (38)11/6/2014 12:52:36 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 136
 
>> second CD123 shot on goal still sitting there, waiting for preclinical <<

from today's release.....

Dr. Dahiyat added, "Based on these data, we have selected XmAb14045, our lead anti-CD123xCD3 bispecific antibody, for IND-enabling studies and cGMP process development and manufacturing at a contract manufacturer. We look forward to bringing this candidate into the clinic within the next 18 months."

investors.xencor.com



To: scaram(o)uche who wrote (38)11/8/2014 4:48:13 PM
From: scaram(o)uche  Respond to of 136
 
>> second CD123 shot on goal still sitting there, waiting for preclinical <<

Timely, the first shot on goal -- CSL362 -- is also moving... difficult to tolerate, hydrocortisone premedication intro'd into protocol.....

ash.confex.com

(pointer from jq123)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News